We use some essential cookies to make this website work.
We’d like to set additional cookies to understand how you use GOV.UK, remember your settings and improve government services.
We also use cookies set by other sites to help us deliver content from their services.
You have accepted additional cookies. You can change your cookie settings at any time.
You have rejected additional cookies. You can change your cookie settings at any time.
Departments, agencies and public bodies
News stories, speeches, letters and notices
Detailed guidance, regulations and rules
Reports, analysis and official statistics
Consultations and strategy
Data, Freedom of Information releases and corporate reports
You may need to tell DVLA if you have malignant melanoma - download the correct form if you need to let them know
The Medicines and Healthcare products Regulatory Agency (MHRA) has today (27 December) approved the advanced melanoma medicine Opdualag (nivolumab-relatlimab) for patients from the age of 12.
Cutaneous malignant melanoma and occupational exposure to (natural) UV radiation in pilots and aircrew.
This document contains a synopsis of causation occurring in melanoma.
This is the council’s note about non-melanoma skin cancer and occupational exposure to (natural) ultraviolet (UV) radiation.
A review of the relationship between melanoma of the eye (‘ocular melanoma’) and occupation.
This document contains a synopsis of causation occurring in Non Melanoma skin cancer.
The regulator has opened a statutory inquiry into patient support and cancer awareness charity Melanoma UK -- Incorporating Factor 50.
Periodically perform skin examinations in patients on bendamustine-containing regimens and consider PML in the differential diagnosis for patients on bendamustine with new or worsening neurological, cognitive, or behavioural signs or symptoms.
Report certain types of medical conditions to DVLA if you're a lorry, bus or coach driver.
Pilot campaign in the Devon, Cornwall and Somerset area urges people to recognise key signs of skin cancer.
Project Orbis is a programme to review and approve promising cancer drugs helping patients access treatments faster.
Advise patients taking hydrochlorothiazide-containing products of the cumulative, dose-dependent risk of non-melanoma skin cancer, particularly in long-term use, and the need to regularly check for (and report) any suspicious skin lesions or moles. Counsel patients to limit exposure to sunlight...
Quarterly updates to the emergency presentations of cancer data by Public Health England.
Don’t include personal or financial information like your National Insurance number or credit card details.
To help us improve GOV.UK, we’d like to know more about your visit today. We’ll send you a link to a feedback form. It will take only 2 minutes to fill in. Don’t worry we won’t send you spam or share your email address with anyone.